Results 221 to 230 of about 85,599,609 (253)

Person‐Reported and Continuous Glucose Monitoring (CGM) Recorded Hypoglycaemia in People With Insulin‐Treated Type 2 Diabetes and Mild to Moderate Chronic Kidney Disease; Post Hoc Analysis From the Hypo‐METRICS Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10664-10669, November 2026.
ABSTRACT Background and Aims People with diabetes and chronic kidney disease (CKD) may be at increased risk of iatrogenic hypoglycaemia. We compared rates of sensor‐detected (SDH) and person‐reported hypoglycaemia (PRH) in people with insulin‐treated Type 2 diabetes (T2D) with and without CKD in the Hypo‐METRICS study.
Julie M. B. Brøsen, Daniel Malmsiø, Patrick Divilly, Gilberte Martine‐Edith, Natalie Zaremba, Namam Ali, Rory J. McCrimmon, Simon Heller, Mark Evans, Bastiaan de Galan, Julia K. Mader, Eric Renard, Allan A. Vaag, Pratik Choudhary, Ulrik Pedersen‐Bjergaard, on behalf of the HypoRESOLVE Consortium, Andrew Pernet, Amy Aldridge, Marcia Henderson‐Wilson, Pernille Banck‐Petersen, Rikke Carstensen, Charlotte Hansen, Sharon Caunt, Sue Hudson, Chloe Husband, Fahad Arshad, Anne Farret, Anne‐Marie Marteil‐Oudrer, Manal Shbat, Lisa Crespy, Jenny Constanza Thibout, Anja Rasing, Jesper Walburgh Schimidt, Daniel Loewenstein, Renate Huijsmans, Pieter Drijver, Daniel Chapman, Jane Kennet, Anna Barnett, Jackie Lindsay   +39 more
wiley   +1 more source

Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10765-10779, November 2026.
ABSTRACT Aims To examine the association between initiation of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and risk of incident depression compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors among adults with newly diagnosed Type 2 diabetes receiving metformin.
Sangwoo Park, Seogsong Jeong, Hye Jun Kim, Dae Ho Lee, Soo Jung Choi, Sang Min Park   +5 more
wiley   +1 more source

Comparison of medication persistence and adherence in type 2 diabetes using a once-weekly regimen of DPP-4 inhibitor compared with once-daily and twice-daily regimens: a retrospective cohort study of Japanese health insurance claims data. [PDF]

Diabetol Int
Miwa T, Yoshida S, Nakajima A, Koto R, Nishimura R.   +4 more
europepmc   +1 more source

Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10780-10794, November 2026.
ABSTRACT Objective Treatment response in type 2 diabetes (T2D) varies widely among individuals. This study aimed to quantify the contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose‐lowering therapies.
S. Garg, R. Kitchen, R. Gupta, L. Donnelly, E. R. Pearson   +4 more
wiley   +1 more source

Cardiorenal Mortality and Safety Outcomes of GLP‐1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10498-10512, November 2026.
ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen, Yu‐Nan Huang, Pei‐Yun Li, Jo‐Ching Chen, Gideon Meyerowitz‐Katz, Shun‐Fa Yang, Pen‐Hua Su   +6 more
wiley   +1 more source

Insulin Efsitora Demonstrates Similar Efficacy and Safety Profiles to Insulin Icodec in Insulin‐Experienced Individuals With Type 2 Diabetes Mellitus: Matching‐Adjusted Indirect Comparisons of QWINT‐3 Versus ONWARDS 2, and QWINT‐4 Versus ONWARDS 4

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10725-10735, November 2026.
ABSTRACT Aims To conduct indirect treatment comparisons (ITCs) of insulin efsitora alfa (efsitora) versus insulin icodec (icodec) in insulin‐experienced individuals with Type 2 Diabetes Mellitus. Methods Efficacy, safety and patient reported outcomes were compared via matching‐adjusted ITCs using results from randomised controlled trials: QWINT‐3 ...
Harpreet S. Bajaj, Marvin Fischer, Michael B. Davidson, Abdul M. Tarafder, Christopher J. Michaels, Rachel H. Tao, Alex Pashley, Jess Amis, Josefine Redig   +8 more
wiley   +1 more source

Summary of Research: Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin Versus Placebo and the DPP-4 Inhibitor Linagliptin Versus Placebo in Young People with Type 2 Diabetes (DINAMO): A Multicentre, Randomised, Double-Blind, Parallel Group, Phase 3 Trial. [PDF]

Diabetes Ther
Laffel LM.
europepmc   +1 more source

Exploratory Analysis of Type 2 Diabetes Mellitus Metabolic Phenotypes and Their Association With Vitamin D Status in Primary Care Patients

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10603-10614, November 2026.
ABSTRACT Aims This study aimed to perform an exploratory characterisation of metabolic phenotypes in primary care patients with type 2 diabetes mellitus (T2DM), using a predefined approach and examine their association with vitamin D status. Materials and Methods This cross‐sectional study included 178 participants randomly selected in Sergipe, Brazil.
Liliane Viana Pires, Matheus Menezes‐Santos, Andréa Costa Goes, Heitor Siqueira Ribeiro, Luana Ferreira Alves, Beatriz Cruz dos Santos, Jéssyca Teles Barreto, Roberta Cristina Vieira Meneses, Ana Mara de Oliveira e Silva, Ana Hermínia Andrade e Silva, Sadraque Eneas de Figueiredo Lucena   +10 more
wiley   +1 more source

Immune Consequences of Metabolic Syndrome and Its Treatment: A Cytokine Perspective

Immunology, Volume 179, Issue 3, Page 390-405, November 2026.
Peripheral blood mononuclear cells (PBMCs) from individuals with metabolic syndrome (MetS) who were not using glucose‐and/or lipid lowering medication (GLLM) exhibited a broader cytokine production profile after in vitro antigen‐specific stimulation than PBMCs from individuals with MetS using such medications and from healthy donors.
Isabela Ghetti Macedo Isaac, Carolina do Prado Servian, Fernanda de Oliveira Feitosa de Castro, João Lucas Lima Calandrini de Azevedo, Ronaldo Moraes Preto, Miriam Leandro Dorta, Daniela Espíndola Antunes, Simone Gonçalves Fonseca   +7 more
wiley   +1 more source